GCG and Hypoglycemia: Such interventions include the incretin-based therapeutics (GLP-1-RAs, e.g., liraglutide or DPP-4 inhibitors and SGLT-2 inhibitors) enhancing glycemic control with a low risk of hypoglycemia.